Skip to content
Peptigraph home

Peptides for Belly fat

The peptides people most often research for belly fat, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Peptides listed
6
With human trials
5
FDA approved (any use)
3
Showing 6 peptides · ordered by search interest for this goal
  1. TesamorelinGHRH analogHuman RCT evidence, 4 of 4eNeurologicalSci 2026, PMID 42382101Human34Animal0Summarised10FDA approved (Egrifta)For belly fatOverview
  2. TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4Arthritis & rheumatology 2026, PMID 41903163Human79Animal1Summarised16FDA approved (Mounjaro, Zepbound)For belly fatOverview
  3. SermorelinGHRH analogHuman observational evidence, 3 of 4Metabolism: clinical and experimental 1997, PMID 9005976Human0Animal0Summarised1Compounded by prescriptionFor belly fatOverview
  4. RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42814954Human4Animal0Summarised13Investigational · phase 3For belly fatOverview
  5. SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40934115Human148Animal5Summarised14FDA approved (Ozempic, Wegovy, Rybelsus)For belly fatOverview
  6. IpamorelinGHRP (ghrelin receptor agonist)No study with an outcome for belly fatPubMed search, 11 Oct 2026Human0Animal0Summarised1Not FDA approved · research chemicalOverview
Read this first

What this list does not show

Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.

Search interest is not evidence

This list follows what people search for and discuss. It says nothing about how well any peptide works.

Animal results may not carry over

Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.

Approval covers specific uses

An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.

Combinations are a separate question

Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.

Belly fat as a medical measure

MedlinePlus says a large waistline, with more body fat around the abdomen than the hips, increases the risk of weight-related health problems.[9]

MedlinePlus notes that BMI does not distinguish between fat, muscle and bone mass.[9]

What trials measured for abdominal fat

Tesamorelin has 34 human-only papers and 14 randomised trials in the belly-fat ledger, tirzepatide 79 and 21, and semaglutide 148 and 30, while sermorelin and ipamorelin have none.

Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); tesamorelin human only 34, animal only 0, rct 14; tirzepatide human only 79, animal only 1, rct 21; sermorelin human only 0, animal only 0, rct 0; semaglutide human only 148, animal only 5, rct 30; ipamorelin human only 0, animal only 0, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.

In a randomised trial in HIV-associated abdominal fat, visceral adipose tissue decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group.[10]

Visceral fat reaccumulated after tesamorelin was discontinued.[11]

A meta-analysis found tesamorelin significantly reduced visceral adipose tissue versus control.[12]

In a head-to-head trial, mean waist circumference fell 18.4 cm with tirzepatide and 13.0 cm with semaglutide.[13]

In a diabetes sub-study, tirzepatide significantly reduced liver fat content and visceral fat volume compared with insulin degludec.[14]

What the FDA label says tesamorelin is for

The Egrifta SV label restricts tesamorelin to excess abdominal fat in HIV-infected adults with lipodystrophy.[15]

The label states that it is not indicated for weight loss management.[15]

Common questions

What are the best peptides for belly fat?

Tesamorelin has the abdominal-fat trial data cited here, in HIV-associated lipodystrophy, and visceral fat reaccumulated after discontinuation.[11]

Do belly fat peptides actually work?

In a randomised trial in HIV lipodystrophy, visceral adipose tissue decreased by 15.2% on tesamorelin and increased by 5.0% on placebo.[10]

Is tesamorelin approved for belly fat?

Only for excess abdominal fat in HIV-infected adults with lipodystrophy, and not for weight loss.[15]

Does tirzepatide reduce waist size?

In a head-to-head trial, mean waist circumference fell 18.4 cm with tirzepatide against 13.0 cm with semaglutide.[13]

Sources

  1. 1The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  2. 2Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
  3. 3Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  4. 4Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
  5. 5Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
  6. 6PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  9. 9Official web pageOfficial web page · web page
  10. 10Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  11. 11Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
  12. 12Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
  13. 13Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
  14. 14Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.The lancet. Diabetes & endocrinology · 2022PMID 35468325Accessed 2 Oct 2026
  15. 15EGRIFTA SV prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.